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ABSTRACT The aim of the present study was to identify the signaling mechanism(s) respon-
sible for the modulation of growth hormone secretagogue receptor type 1a (GHSR1a)-asso-
ciated Akt activity. Ghrelin leads to the activation of Akt through the interplay of distinct 
signaling mechanisms: an early Gi/o protein-dependent pathway and a late pathway mediated 
by β-arrestins. We found that the Src homology 2–containing protein tyrosine phosphatase 
(SHP-1) was an essential molecule in both Gi/o protein–dependent and β-arrestin–mediated 
pathways. More specifically, the role of SHP-1 in the Gi/o protein–dependent pathway was 
demonstrated by the fact that the overexpression of a catalytically defective SHP-1 augments 
tyrosine phosphorylation of the PI3K regulatory subunit p85, leading to an increase in the 
phosphorylation of cSrc and phosphoinositide-dependent protein kinase 1, and finally acti-
vating Akt. The presence of SHP-1 in the β-arrestin–scaffolded complex and its attenuating 
effect on the cSrc and Akt activities verified that SHP-1 regulates not only the Gi/o protein–
dependent pathway but also the β-arrestin–mediated pathway. Assays performed in preadi-
pocyte and adipocyte 3T3-L1 cells showed SHP-1 expression. According to our results in 
HEK-GHSR1a cells, ghrelin stimulated SHP-1 phosphorylation in 3T3-L1 cells. The increase in 
ghrelin-induced Akt activity was enhanced by small interfering RNA of SHP-1 in preadipocyte 
3T3-L1 cells. These results were reproduced in white adipose tissue obtained from mice, in 
which SHP-1 exhibited higher expression in omental than in subcutaneous tissue. Further-
more, this pattern of expression was inverted in mice fed a high-fat diet, suggesting a role for 
SHP-1 in controlling ghrelin sensitivity in adipose tissue. Indeed, SHP-1 deficiency was associ-
ated with augmented ghrelin-evoked Akt phosphorylation in omental tissue, as well as de-
creased phosphorylation under overexpression of SHP-1 in subcutaneous tissue. These find-
ings showed a novel role for SHP-1 in the regulation of Akt activity through the modulation 
of the ghrelin/GHSR1a system signaling.
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INTRODUCTION
The main physiological functions of ghrelin as a growth hormone 
secretagogue, an orexigenic peptide, and a long-term regulator of 
energy homeostasis are critically regulated through the growth hor-
mone secretagogue receptor type 1a (GHSR1a), a receptor belong-
ing to the G protein–coupled receptor family (GPCR). This receptor 
has traditionally been linked to heterotrimeric G proteins and down-
stream second-messenger molecules (Castañeda et al., 2010). How-
ever, for a number of years, biochemical and cellular studies have 
suggested that some aspects of GHSR1a-mediated signaling occur 
in parallel to G-protein activation via multifunctional adaptor pro-
teins known as β-arrestins (Camiña et al., 2007; Lodeiro et al., 2009). 
The β-arrestins constitute a small family of gene products originally 
identified as molecules that desensitize GPCR signaling (Kovacs 
et al., 2009). On ghrelin binding, GHSR1a undergoes conforma-
tional changes that result in the activation of heterotrimeric G pro-
teins. This step is followed by receptor phosphorylation that leads to 
β-arrestin recruitment, which then sterically interdicts further cou-
pling to G proteins, leading to receptor desensitization. β-Arrestins 
also mediate endocytosis of GHSR1a, leading to receptor recycling 
(Camiña et al., 2004; Holliday et al., 2007). In addition to their role in 
terminating G-protein signaling, recent studies demonstrated that 
β-arrestins also function as scaffold molecules for ghrelin-activated 
signaling networks, such as ERK1/2 (Camiña et al., 2007) and Akt/
protein kinase B (Lodeiro et al., 2009), which are defined as “sig-
nalosomes” (Kovacs et al., 2004). The signaling mechanisms that 
underlie the activation of the mitogenic ERK growth response by the 
GHSR1a result from both classical G protein–regulated effectors 
and β-arrestin–dependent ERK1/2 recruitment (Camiña et al., 2007). 
One pathway is Gi/o-dependent, and it is mediated by phosphati-
dylinositol 3-kinase (PI3K), protein kinase Cε, and the nonreceptor 
tyrosine kinase, cSrc. The second pathway is Gq/11-dependent and 
involves the activation of protein kinase C α/β and cSrc. A third 
pathway involves the recruitment of GHSR1a, cSrc, Raf-1, and 
ERK1/2 into a β-arrestin–scaffolded complex. This complex persists 
for extended periods, and it is probably determined by its stability.
Over the past decade, the serine/threonine kinase Akt emerged 
as a critical signaling node in the regulation of metabolism, apopto-
sis, transcription, and the cell cycle, placing it at the center of human 
physiology and disease (Manning and Cantley, 2007). The GHSR1a 
is implicated in Akt signaling through a complex interplay of distinct 
signaling mechanisms: an early Gi/o protein–dependent pathway 
and a late pathway mediated by β-arrestins. The starting point is the 
Gi/o protein–dependent PI3K activation that leads to the membrane 
recruitment of Akt, which is phosphorylated at Y by cSrc, with sub-
sequent phosphorylation at the A loop (T308) and the hydrophobic 
motif (HM; S473) by phosphoinositide-dependent protein kinase 1 
(PDK1) and mammalian target of rapamycin complex 2 (mTORC2), 
respectively. Once the receptor is activated, a second signaling 
pathway mediated by β-arrestins 1 and 2 is activated, involving the 
recruitment of cSrc and Akt. This β-arrestin–scaffolded complex 
leads to full activation of Akt through PDK1 and mTORC2, which are 
not physically associated to the complex. Both G protein– and 
β-arrestin–mediated pathways are temporally different and act in a 
sequential way where β-arrestin–scaffolded signaling complex per-
sists for prolonged periods (Lodeiro et al., 2009).
The present study focuses on the mechanisms regulating 
GHSR1a-associated Akt activity, and emphasizes the implication of 
reversible tyrosine phosphorylation of upstream targets of Akt 
through the cytoplasmic protein Src homology-2 domain–contain-
ing phosphatase-1 (SHP-1), a protein tyrosine phosphatase (PTP). 
SHP-1 is a well-known inhibitor of activation-promoting signaling 
cascades in hematopoietic cells (Tonks, 2006; Lorenz, 2009) and in-
sulin tissue targets (Dubois et al., 2006), but its potential role in 
ghrelin/GHSR1a system is unknown. These molecular mechanisms 
were investigated in HEK 293 cells stably expressing the GHSR1a 
(HEK-GHSR1a) as a model system to follow the interaction of spe-
cific proteins and the roles, if any, played by G proteins and 
β-arrestins. Results were confirmed in 3T3-L1 cells, as both preadi-
pocyte and adipocytes cells, and potential physiological repercus-
sions based on ghrelin signaling to Akt were studied in white adi-
pose tissue (WAT) obtained from mice fed a high-fat diet (HFD).
RESULTS
Figure 1A shows that SHP-1 activity, measured as SHP-1 phosphory-
lation in the C-terminal Y536 residue (pSHP-1(Y536); Zhang et al., 
2003), reached maximal levels within 10 min of ghrelin stimulation 
(100 nM), staying at this level for at least 60 min in HEK-GHSR1a 
cells. The role of SHP-1 on ghrelin-induced phosphorylation of the 
Akt HM (S473; pAkt(S473)) and the A loop (T308; pAkt(T308)) was 
evaluated by transient transfection of dominant-negative catalyti-
cally inactive SHP-1 (SHP-1dn). Ghrelin induced Akt phosphoryla-
tion at both pAkt(S473) and pAkt(T308) after 5 min of treatment 
(Figure 1B). In cells overexpressing SHP-1dn, the ghrelin-induced 
pAkt(S473) and pAkt(T308) levels were significantly higher after 
5 and 10 min of treatment (Figure 1B). This effect was more promi-
nent in the case of pAkt(T308) and remained up to 20 min after 
ghrelin treatment, while no difference was observed in ghrelin-in-
duced pAkt(S473) levels in SHP-1dn–transfected cells and control 
cells at this time point.
The role of SHP-1 on PI3K, cSrc, and PDK1, key nodes for Akt A 
loop (T308) phosphorylation, was evaluated in SHP-1dn–overex-
pressing cells. SHP1 associates with PI3K and dephosphorylates the 
kinase at Y688, a residue that maps within the p85 subunit (Cuevas 
et al., 2001). Control and SHP-1dn–transfected were evaluated for 
p85 Y phosphorylation under ghrelin stimulation (100 nM, 5 min). 
Results from p85 immunoprecipitation analysis revealed the level of 
p85 Y phosphorylation induced by ghrelin (100 nM, 5 min) to be 
markedly higher in SHP-1dn–transfected cells compared with con-
trol cells (Figure 1C). cSrc is regulated by GHSR1a through a Gi/o-
dependent pathway involving PI3K and PKCε by phosphorylating 
the Y416 residue within the kinase domain (pcSrc(Y416)) which is 
important for its tyrosine kinase activity (Lodeiro et al., 2009). Results 
from immunoblot analysis revealed markedly higher pcSrc(Y416) 
levels in cells overexpressing SHP-1dn than in control cells under 
ghrelin stimulation (100 nM; Figure 1D), providing evidence that 
cSrc activity is regulated by Y416 dephosphorylation by SHP-1. The 
effect of SHP-1 on PDK1 A-loop(S241) phosphorylation (pPDK1(S241)) 
was next evaluated. Consequently, overexpression of SHP-1dn in-
creased ghrelin-induced pPDK1(S241) levels (Figure 1D). These data 
indicated that ghrelin-induced p85, cSrc, PDK1, and, subsequently, 
Akt A-loop (T308) phosphorylation depended on tyrosine phospho-
rylation events restrained by SHP-1.
The finding that Akt phosphorylation on HM(S473) was also 
affected by SHP-1dn led us to analyze the effect of this tyrosine 
phosphatase on mTORC2 (mTORC2: Rictor, mLST8, mSin1 vari-
ants, Protor/PRR5 and mTOR kinase). While the catalytic activity 
of mTORC2 is stimulated by ghrelin (Lodeiro et al., 2009), the 
molecular mechanisms regulating its cellular activities remain 
unknown. Therefore mTORC2 was immunoprecipitated with 
antibody to Rictor from lysates of ghrelin-treated cells (100 nM, 
5 min), transfected with SHP-1dn or controls, and subjected to 
immunoblot with anti-phosphotyrosine. However, the lack of dif-
ferences between ghrelin-treated and control cells discarded 
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2009) in SHP-1dn–transfected cells. Immunoprecipitation of 
β-arrestin 1 or β-arrestin 2 revealed a physical association between 
β-arrestins and pSHP-1(Y536), which increased substantially under 
ghrelin stimulation to control cells (Figure 2B). A 10-min ghrelin 
stimulation of the cells overexpressing SHP-1dn effectively en-
hanced the ghrelin response on β-arrestin–associated pAkt(S473) 
and pcSrc(Y416) phosphorylation, verifying that SHP-1 regulates not 
only the Gi/o protein–dependent pathway but also the pathway me-
diated by β-arrestin–associated complex (Figure 2B).
Src is able to phosphorylate SHP-1 on Y536 in vitro, leading to 
an increase in the activity of the phosphatase (Somani et al., 1997; 
Frank et al., 2004). To investigate this possibility, ghrelin-stimu-
lated cells with siRNA targeting cSrc were evaluated for SHP-1 
activity. As indicated in Figure 2C, siRNA experiments targeting 
cSrc reduced its expression by 54 ± 2%. cSrc siRNA decreased 
ghrelin-activated SHP-1(Y536) phosphorylation (73 ± 2% at 10-min 
ghrelin stimulation with respect to siRNA control) for all times 
the modulation of SHP-1 on mTORC2 activity (Supplemental 
Figure S1).
Once the GHSR1a is activated, a second signaling pathway is 
mediated by β-arrestins 1 and 2, involving the recruitment of at least 
the β-arrestins, cSrc, and Akt. Therefore the effects of small interfer-
ing RNA (siRNA)-mediated suppression of β-arrestins 1 and 2 ex-
pression were examined on the kinetics of pSHP-1(Y536) following 
ghrelin stimulation. siRNA experiments targeting β-arrestin 1 or 
β-arrestin 2 reduced their expression by 50 ± 2% and 65 ± 4%, re-
spectively (Figure 2A). β-arrestin 1 and β-arrestin 2 siRNAs decreased 
ghrelin-activated pSHP-1(Y536) with respect to siRNA control, with 
maximal inhibitory effect at the later time points (62 ± 3% and 51 ± 
5% at 10 min for β-arrestin 2 and β-arrestin 1 siRNA, respectively 
[Figure 2A]). To further validate the connection between β-arrestin–
scaffolded complex and SHP-1, immunoprecipitations of β-arrestins 
were assayed at 10 min corresponding to the maximum of β-arrestin/
GHS-1a complex formation (Camiña et al., 2007; Lodeiro et al., 
FIGURE 1: Effects of overexpression of dominant-negative SHP-1 (SHP-1dn) on ghrelin-activated Akt signaling cascade. 
(A) Time course of the effect of ghrelin (100 nM) on pSHP-1(Y536). (B) Ghrelin-induced Akt HM (S473) and A-loop (T308) 
phosphorylation in the absence (vector control: control) or presence of SHP-1dn. Effect of vector control (vector) and 
SHP-1dn on SHP-1 and GHSR1a expression in HEK-GHSR1a cells is shown on the left. (C) Basal and ghrelin-induced Y 
phosphorylation and expression of p85 regulatory subunit of PI3K in vector control and SHP-1dn–transfected HEK-
GHSR1a cells. IP, immunoprecipitation; IB: immunoblot. (D) Ghrelin-induced pcSrc(Y416) and pPDK1(S241) measured in 
control (vector control) and SHP-1dn–transfected HEK-GHSR1a cells. Immunoblots in (A), (B), (C), and (D) are 
representative of three independent experiments. Data are expressed as mean ± SE obtained from intensity scans of 
three independent experiments. *p < 0.05 vs. control values.
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pression by 58 ± 1%. SHP-1 siRNA increased ghrelin-activated 
pAkt(T308) (91 ± 3% at 10 min of ghrelin stimulation) and pAkt(S473) 
(36 ± 1% at 10 min of ghrelin stimulation) with respect to siRNA 
control. SHP-1 was detected immunohistochemically in omental 
and subcutaneous WAT obtained from mice under normal chow 
(control) and HFD (Figure 4A). pSHP-1(Y536) was significantly in-
creased in ghrelin-stimulated omental and subcutaneous WAT ex-
plants from control mice in vitro (100 nM, 10 min). This activation 
was higher in omental than in subcutaneous tissue, correlating with 
a higher expression for the SHP-1 in the omental tissue (Figure 4B). 
Similarly, pSHP-1(Y536) was significantly increased in ghrelin-stim-
ulated omental and subcutaneous WAT explants from HFD mice in 
vitro (100 nM, 10 min). This activation, however, was higher in sub-
cutaneous than in omental tissue, correlating with a higher expres-
sion for the SHP-1 in the subcutaneous tissue from HFD mice 
tested, suggesting that SHP-1 activation is almost entirely medi-
ated by cSrc.
SHP-1 is largely expressed in hematopoietic cells, but has also 
been detected in liver and skeletal muscle (Plutzky et al., 1992; 
Norris et al., 1997; Dubois et al., 2006). Results of immunoblot 
analysis demonstrated moderate SHP-1 expression in 3T3-L1 cells 
and WAT compared with liver or spleen (Figure 3A). In preadipo-
cyte and adipocyte 3T3-L1 cells, SHP-1 was also detected by im-
munohistochemistry (IHC) in the cytoplasm, with enrichment in the 
perinuclear region (Figure 3B). Determination of pSHP-1(Y536) in 
ghrelin-treated (100 nM) 3T3-L1 cells confirmed the stimulatory 
ghrelin effect on SHP-1 activity in preadipocytes and adipocytes 
(Figure 3C). Ghrelin-stimulated 3T3-L1 preadipocyte cells with 
siRNA targeting SHP-1 were evaluated for Akt activity. As indicated 
in Figure 3D, siRNA experiments targeting SHP-1 reduced its ex-
FIGURE 2: Functional relation between GHSR1a-associated, β-arrestin–scaffolded complex and SHP-1 activity. 
(A) Ghrelin-induced pSHP-1(Y536) in the absence (−) or presence (+) of β-arrestin 1 or 2 siRNA. Left, the immunoblot 
analysis of β-arrestin and GHSR1a expressions in control siRNA and β-arrestin 1 or 2 siRNA-transfected HEK-GHSR1a 
cells. (B) Effect of ghrelin (100 nM, 10 min) on the assembly of complexes containing β-arrestins 1 (left) and 2 (right), 
pAkt(S473), pcSrc(Y416), and pSHP-1(Y536) measured in control (vector control) and SHP-1dn–transfected HEK-GHSR1a 
cells. IP, immunoprecipitation; IB: immunoblot. (C) Ghrelin-induced pSHP-1(Y536) in the absence (−) or presence (+) of 
cSrc siRNA. Left, shows the immunoblot analysis of cSrc and GHSR1a expressions in control siRNA and cSrc siRNA-
transfected HEK-GHSR1a cells. Immunoblots in (A), (B), and (C) are representative of three independent experiments. 
Data are expressed as mean ± SE obtained from intensity scans of three independent experiments. *p < 0.05 vs. control 
values.
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DISCUSSION
Over the past several years, much progress has been made in eluci-
dating intracellular signaling events mediating metabolic actions of 
the ghrelin/GHSR1a system. However, the molecular processes that 
mediate the inactivation of these events remain less defined. We 
previously have demonstrated that the GHSR1a-associated signal-
ing pathways trigger Akt activation, with cSrc functioning as a switch 
that initiates the Akt pathway associated to both the Gi/o protein–
dependent pathway and the β-arrestin–scaffolded complex (Lodeiro 
et al., 2009). The current study indicates that SHP-1 is a critical met-
abolic piece in the ghrelin/GHSR1a signal transduction pathway. 
More specifically, our work offers four major findings related to the 
regulation of Akt activity in response to ghrelin. First, activation of 
SHP-1 was cSrc-dependent and involved the interplay of G protein– 
and β-arrestin–dependent signaling pathways. Second, SHP-1 at-
tenuated the action of ghrelin by dephosphorylating PI3K and cSrc, 
(Figure 4B). This was followed by increased ghrelin-stimulated 
pAkt(T308) and pAkt(S473) levels in omental WAT of HFD mice 
compared with omental WAT of control mice (∼2.0- and 0.8-fold 
higher, respectively). In contrast, ghrelin-induced pAkt(T308) and 
pAkt(S473) levels were ∼38% and ∼33% less in subcutaneous WAT 
of HFD mice relative to subcutaneous WAT of control mice, re-
spectively (Figure 4C). No changes were detected in total Akt, 
GHSR1a, and p85 levels in all instances (Figure 4, C–E). cSrc ex-
pression was markedly enhanced in omental and subcutaneous 
WAT of HFD mice compared with WAT of control mice (∼1.9- and 
∼1.6-fold, respectively; Figure 4F). PDK1 levels were enhanced in 
subcutaneous WAT of HFD mice relative to control (∼0.9-fold), 
although they were not altered in omental WAT of HFD mice 
(Figure 4G). On the contrary, mTOR levels were augmented in 
omental WAT of HFD mice and were diminished in subcutaneous 
WAT of HFD mice (Figure 4H).
FIGURE 3: Role of SHP-1 in 3T3-L1. (A) Immunoblot analysis of SHP-1 in extracts from 3T3-L1 cells, WAT, skeletal 
muscle, liver, and spleen of control mice (n = 10). Same amount of protein (40 μg) was used for this analysis. Results 
were expressed as fold increase of SHP-1 level in liver. (B) Immunocytochemical detection of SHP-1 in 3T3-L1 
preadipocyte and adipocyte cells (objective magnification: 40×). SHP-1 immunostaining was mainly concentrated in 
perinuclear compartments in both 3T3-L1 cells. (C) Time course of the effect of ghrelin (100 nM) on pSHP-1(Y536) in 
3T3-L1 preadipocyte and adipocyte cells. pSHP-1(Y536) was expressed as a fold increase of control (unstimulated) cells. 
Immunoblots are representative of three independent experiments. (D) Ghrelin-induced Akt HM (S473) and A-loop 
(T308) phosphorylation in the absence (−) or presence (+) of SHP-1 siRNA in 3T3-L1 preadipocyte cells. Left, the 
immunoblot analysis of SHP-1 and GHSR1a expressions in control siRNA and SHP-1 siRNA-transfected HEK-GHSR1a 
cells. Data are expressed as mean ± SE obtained from intensity scans of three independent experiments. *p < 0.05 vs. 
control values.
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or positive (Krautwald et al., 1996; Wishcamper et al., 2001) modu-
lator of a great variety of receptors. The results presented here are 
in favor of the role of SHP-1 as a negative regulator of the ghrelin/
GHSR1a signaling. The expression of catalytically inactive SHP-1 in-
creased ghrelin-induced Akt phosphorylation, with a greater reper-
cussion on the Akt A loop (T308) phosphorylation. While much of 
the characterization of SHP-1 is centered on its function as a PTP, the 
regulation of its activation is still a matter of controversy (Lorenz 
et al., 1994; Uchida et al., 1994; Zhang et al., 2003). Although this 
thereby inhibiting Akt signaling. Third, SHP-1 was expressed and 
stimulated by ghrelin in WAT. Fourth, SHP-1 expression in WAT was 
dynamically regulated in response to high-fat feeding. Thus SHP-1 
would define the impact of the ghrelin/GHSR1a-associated biologi-
cal response, at least on Akt signaling.
SHP-1 plays a variety of roles in multiple signal transduction 
events via Y dephosphorylation (Neel and Tonks, 1997; Neel et al., 
2003; Zhang et al., 2000), acting as a negative (Klingmüller et al., 
1995; Somani et al., 1997; Kozlowski et al., 1998; Feng et al., 2002) 
FIGURE 4: Role of SHP-1 in WAT. (A) Immunohistochemical detection of SHP-1 in subcutaneous and omental WAT 
obtained from control and HFD-treated mice (objective magnification: 20×). Decreased SHP-1 immunostaining was 
evident in omental WAT compared with control mice. (B) Effect of ghrelin (100 nM, 10 min) on pSHP-1(Y536) in 
omental and subcutaneous WAT explants in vitro from control and HFD mice. pSHP-1(Y536) levels were expressed as 
a fold increase of control (unstimulated) WAT (n = 10 per group). Expression levels of SHP-1 in omental and 
subcutaneous WAT obtained from control and HFD mice. (C) Effect of ghrelin (100 nM, 10 min) on pAkt(T308) and 
pAkt(S473) in omental and subcutaneous WAT explants in vitro from control and HFD mice. pAkt levels were 
expressed as a fold increase of control (unstimulated) WAT (n = 10 per group). Expression levels of Akt in omental 
and subcutaneous WAT obtained from control and HFD mice. (D–E) Expression levels of GHSR1a (D), p85(E), cSrc (F), 
PDK1 (G), and mTOR (H) in omental and subcutaneous WAT obtained from control and HFD mice (n = 10 per group). 
Data are expressed as mean ± SE obtained from intensity scans of animal groups (control and stimulated WAT from 
SD and HFD mice). *p < 0.05 vs. control values.
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lated by this PTP. According to our results in cell culture models, 
ghrelin activated SHP-1 in WAT. Furthermore, the level of SHP-1 
phosphorylation correlated to the SHP-1 levels associated to spe-
cific WAT depots. Taken together, these results point to a higher 
ghrelin effect in subcutaneous than omental WAT in normal condi-
tions. Our study took advantage of signaling defects triggered by 
modification of the SHP-1 expression in HFD mice to determine the 
contribution of this PTP. While the low SHP-1 levels in omental WAT 
from HFD mice led to the augmentation of ghrelin-evoked Akt re-
sponse, the high SHP-1 levels in subcutaneous depots led to a par-
tial attenuation of Akt response, showing a differential fine-tuning of 
the signal transduction between individual WAT depots. This effect 
was more evident on the A loop (T308) than in the HM (S473) phos-
phorylation. This differential effect was also observed in HEK-GH-
SR1a and 3T3-L1 cells, providing a suitable model for the analysis of 
the signaling events of this process. SHP-1 attenuated PDK1 activity 
through PI3K with no apparent effect on mTORC2. This is further 
supported by the fact that both the A-loop (T308) and the HM (S473) 
phosphorylations are independent (Lodeiro et al., 2009). Analysis of 
initial steps in ghrelin signaling to Akt revealed modified levels for 
cSrc, PDK1, and mTOR in WAT from mice fed with HFD relative to 
control mice, while no changes in Akt, GHSR1a, and p85 expression 
were detected. However, this pattern does not appear to explain 
the differences in Akt activity detected between both groups. In 
fact, enhanced cSrc and PDK1 expression in subcutaneous WAT 
from mice fed with HFD does not counteract the attenuation of 
ghrelin-evoked Akt phosphorylation.
One of the main characteristics of adipose tissue is its extreme 
plasticity, which allows it to respond promptly to changes in nutri-
ent intake through adipocyte hypertrophy and/or hyperplasia, de-
pending on the fat depot and fat-cell size (Wajchenberg, 2000). In 
this regard, omental adipose tissue accumulation is correlated to a 
cluster of diabetogenic, atherogenic, prothrombotic, and proin-
flammatory metabolic abnormalities known as the metabolic syn-
drome (Després, 2006). Due to the close ties between the SHP-1 
expression pattern in WAT and its regulation in a positive energy 
balance situation, it is possible to speculate about its role in the 
enlargement of WAT in obesity. Accumulation of fat, and particu-
larly omental fat, is associated with decreased SHP-1 levels, with 
the consequent magnification of ghrelin response, resulting in in-
creased size and number of fat cells. Therefore SHP-1 may contrib-
ute to the dissimilar responses to overfeeding in the different fat 
depots.
In conclusion, and as summarized in Figure 5, we have identified 
the SHP-1 tyrosine phosphatase as a negative regulator of ghrelin 
signaling. Our data are consistent with a model in which ghrelin-ac-
tivated Akt translocates to the plasma membrane through the bind-
ing of its pleckstrin homology domain to the second messenger 
PtdIns(3,4,5)P3 generated by PI3K, which is activated through the 
Gi/o protein–dependent signaling pathway. Akt is phosphorylated at 
Y by the membrane-bound cSrc. This Y phosphorylation is followed 
by phosphorylation of the Akt A loop (T308) and the HM (S473) by 
PDK1 and mTORC2, respectively. Once the receptor is activated, a 
second signaling pathway is mediated by β-arrestins 1 and 2, involv-
ing the recruitment of GHSR1a, cSrc, and Akt into a β-arrestin–
scaffolded complex. In both signaling pathways, cSrc phosphory-
lates the SHP-1 C-terminus (Y536), which exerts an inhibitory effect 
on activity of PI3K and Akt. Consequently, cSrc functions as a switch 
that controls the Akt pathways associated to both the Gi/o protein–
dependent pathway and β-arrestin–scaffolded complex. Although 
further studies are required, the current data show that SHP-1 is ex-
pressed in WAT, one of the target tissues of ghrelin, modulating 
uncertainty remains, it was demonstrated that the Y phosphoryla-
tion of the C-terminal (Y536) on SHP-1 increases its PTP activity 
(Uchida et al., 1994; Frank et al., 2004). Our results showed that 
ghrelin is able to phosphorylate SHP-1 at the C-terminus Y536 in 
intact cells and WAT. Additionally, our study showed that the abla-
tion of cSrc by siRNA impaired ghrelin-stimulated C-terminus Y536 
phosphorylation of SHP-1. With this result, cSrc was located as an 
upstream signal that regulates the phosphorylation and activation of 
SHP-1, which is in agreement with previous reports showing that Src 
activates SHP-1 (Frank et al., 2004). This is also consistent with re-
cent works in which angiotensin II AT2 receptor regulates SHP-1 
activity through Src activation (Feng et al., 2002; Alvarez et al., 2008). 
This new data, together with our previous findings (Lodeiro et al., 
2009), support the idea that cSrc operates as a “switch,” in concert 
with PI3K, for the modulation of Akt activity in response to ghrelin.
Analysis of the upstream targets in ghrelin signaling for Akt acti-
vation under the expression of catalytically inactive SHP-1 revealed 
increased ghrelin-induced Y phosphorylation of p85 regulatory sub-
unit of PI3K. Our data confirm that Y-phosphorylated p85 is a target 
of SHP-1, and cells lacking SHP-1 increased PI3K activity, as previ-
ously described for other factors (Imani et al., 1997; Yu et al., 1998; 
Cuevas et al., 1999; Theodoropoulou et al., 2006). The inhibitory 
effect of SHP-1 on PI3K activity is a consequence of its Y dephos-
phorylation (Y688), a residue that, when phosphorylated, interacts 
with the p85 N-terminal SH2 domain releasing the inhibitory activity 
of p85 on the p110 catalytic subunit (Imani et al., 1997; Yu et al., 
1998; Cuevas et al., 1999). In fact, activation of downstream PI3K 
targets, PDK1 [pPDK1(S241)] and cSrc [pcSrc(Y416)], is increased in 
cells lacking SHP-1 under ghrelin stimulation. This is also consistent 
with the increase of ghrelin-stimulated A-loop (T308) phosphoryla-
tion of Akt in the context of SHP-1 deficiency.
The presence of a pathway involving receptor endocytosis is 
supported by the fact that depletion of β-arrestins 1 and 2 using 
specific siRNAs reduced the magnitude of the ghrelin-stimulated 
C-terminus Y536 phosphorylation of SHP-1. Coimmunoprecipita-
tion assays revealed that the β-arrestins function as adaptors, re-
cruiting SHP-1 to the ghrelin-occupied receptor through the forma-
tion of β-arrestin complexes. This is also consistent with the increase 
of ghrelin-stimulated Akt phosphorylation in the context of func-
tional SHP-1 deficiency. The mechanism of activation of SHP-1 as-
sociated to β-arrestins is not completely delineated. Available data 
suggest that cSrc is essential for Akt activation, even when cSrc is 
associated to β-arrestins (Lodeiro et al., 2009). Given that cSrc is re-
cruited to GHSR1a-β-arrestin complex to initiate Akt phosphoryla-
tion upon ghrelin stimulation (Lodeiro et al., 2009), it was plausible 
to hypothesize that SHP-1 interacts with the cSrc associated to this 
complex, exerting a modulation on cSrc activity, as p85 is not associ-
ated to the GHSR1a-β-arrestin complex (Camiña et al., 2007). Inter-
estingly, both β-arrestin 1 and β-arrestin 2 are required to promote 
the activation of SHP-1. The requirement of both proteins supports 
the need to form heterodimers to activate the β-arrestin–dependent 
signaling pathway for GHSR1a.
Ghrelin plays a significant role in the regulation of adipogenesis 
and lipid storage in WAT (Wells, 2009). At the cellular level, ghrelin-
activated Akt is both necessary and sufficient to drive these pro-
cesses, as Akt plays an essential role in adipogenesis (Xu and Liao, 
2004; Zhang et al., 2009). The implication that SHP-1 is a negative 
regulator of ghrelin activity raises the possibility that this PTP is one 
of the critical signaling components for ghrelin action and essential 
for proper regulation of Akt-dependent processes. In fact, the dis-
similar SHP-1 expression in subcutaneous and omental fat suggests 
that the ghrelin sensitivity of these specific depots may be modu-
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Upstate Technology (Lake Placid, NY). Anti–β-arrestin 1 goat 
polyclonal, anti–β-arrestin 2 mouse monoclonal, anti–SHP-1, anti-
pSHP-1 (Y536), and anti-cSrc rabbit polyclonal antibodies were 
from Santa Cruz Biotechnology (Santa Cruz, CA). β-arrestin 1 
siRNA, β-arrestin 2 siRNA, cSrc siRNA, SHP-1 siRNA, and siRNA 
control were from Santa Cruz Biotechnology. Anti–rabbit horse-
radish peroxidase was from GE-Amersham (Buckinghamshire, 
UK), while anti-goat horseradish peroxidase was from Santa Cruz 
Biotechnology. Rabbit anti–rat β-arrestin 1C-terminal (A1CT) 
antiserum was provided by R. J. Lefkowitz (Duke University 
Medical Center, Durham, NC).
ghrelin signaling to Akt and determining ghrelin sensitivity in WAT 
based on adipose depot differences.
MATERIALS AND METHODS
Materials
Human ghrelin was obtained from Global Peptide (Fort Collins, 
CO). Anti–p44/42 MAPK, anti-pcSrc (Y416), anti–pAkt HM (S473), 
anti–pAkt A-loop (T308), and anti-pPDK1 (S241) rabbit polyclonal 
antibodies were from Cell Signaling Technology (Beverly, MA). 
Anti-Rictor rabbit polyclonal was from Bethyl Laboratories 
(Montgomery, TX). Anti-pY rabbit polyclonal antibody was from 
FIGURE 5: Model of SHP-1 activation and modulation on ghrelin signaling to Akt. Ghrelin binding to GHS-R1a activates 
the generation of the second messenger PtdIns(3,4,5)P3 (PIP3) by PI3K activation through Gi/o protein–dependent 
signaling pathway. Akt translocates to the plasma membrane by binding to PIP3, where it is phosphorylated at Y by the 
membrane-bound cSrc. Activation of cSrc induced phosphorylation of SHP-1, attenuation of p85 subunit from PI3K and 
PDK1, and phosphorylation of Akt. SHP-1 activation regulates cSrc activity by attenuation of Y416 phosphorylation. 
Once the receptor is activated, a second signaling pathway is mediated by β-arrestins 1 and 2, involving the recruitment 
of GHS-R1a, cSrc, SHP-1, and Akt into a β-arrestin–scaffolded complex.
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SDS-polyacrylamide gels and transferred to nitrocellulose mem-
branes. The blots were incubated with 5% nonfat dry milk in TBST 
(Tris-HCl, pH 8.0, 20 mM; NaCl, 150 mM; Tween-20, 0.1% [vol/vol]; 
used for all incubation and washing steps) for 1 h. Next blots were 
incubated with the corresponding antibodies according to the man-
ufacturer’s instructions. The blots were subsequently incubated with 
the corresponding peroxidase-conjugated IgG antibody. After 
washing, signals were visualized using an enhanced chemilumines-
cence detection system (GE-Amersham).
Immunoprecipitation
Serum-starved cells were stimulated with ghrelin for the indicated 
time period at 37°C and lysed in ice-cold nondenaturing NP-40 
solubilization buffer (immunoprecipitation lysis buffer [ILB]: Tris-HCl, 
pH 7.5, 20 mM; NaCl, 150 mM; EDTA, 1 mM; NP-40, 1% [vol/vol]; 
protease inhibitor cocktail [Sigma]; phosphatase inhibitor cocktail 
[Sigma]). Total protein (500 μg) was prewashed with 20 μl of 50% 
protein A/G-agarose (Santa Cruz Biotechnology) for 30 min at 4°C, 
and then incubated with 1 μg of the corresponding antibody over-
night at 4°C, which was followed by addition of 40 μl of 50% protein 
A/G for 2 h at 4°C. After being washing twice with ILB, the pelleted 
beads were resuspended in Laemmli sample buffer. Proteins were 
then analyzed by 10% SDS-polyacrylamide gels, which was followed 
by immunoblotting.
siRNA silencing of gene expression
Chemically synthesized double-stranded siRNA duplexes (with 
3′ dTdT overhangs) were purchased from Santa Cruz Biotech-
nology for the following targets: β-arrestin 1 (5′-AAAGCCUU-
CUG CGCGGAGAAU-3′), β-arrestin 2 (5′-AAGGACCGCAAA-
GUG UUUGUG-3′, 5′-AAAGCCUUCUGCGCGGAGAAU-3′, 
5′-AAGGACCGCAAA GUGUUUGUG-3′), cSrc (5′-CUCGGCUCAUU-
GAAGACA-3′, 5′-UGACUGAGCUCACCACAAA-3′, 5′-CCUCAU-
CAUAGCAAUAACA-3′, 5′-GUAGAUUUCAGAUGACUAU-3′) and 
SHP-1. A nonsilencing RNA duplex was used as a control for 
all siRNA experiments. Cells were transfected with Lipofectamine 
2000 (Invitrogen), according to the manufacturer’s instructions. 
Silencing was quantified by immunoblotting. Only experiments with 
verified silencing were used.
IHC
3T3-L1 cells were cultured on coverslips and differentiated into 
adipocytes. Cells were fixed on coverslips in 96% ethanol. WAT 
samples were fixed by immersion in 10% buffered formalin for 
24 h, dehydrated, and embedded in paraffin using a standard pro-
cedure. Sections (5 μm thick) were mounted on Histobond Adhe-
sion Microslides (Paul Marienfeld, Lauda-Königshofen, Germany), 
dewaxed, and rehydrated. Slides were consecutively incubated 
with: 1) anti–SHP-1 rabbit polyclonal antibody at a dilution of 1:100 
in Dako ChemMate antibody diluent (Dako, Glostrup, Denmark); 
2) EnVision peroxidase rabbit (Dako, Glostrup, Denmark), which 
was used as the detection system; 3) 3,3′-diaminobenzidine-tetra-
hydrochloride (Dako Liquid DAB + Substrate-chromogen system). 
Cell and WAT sections were faintly counterstained with Harris’s he-
matoxylin. Substitution of the primary antibody with PBS was used 
as a negative control.
Data analysis
The data from the immunoblot analysis were normalized to control 
bands, and the results were expressed as the mean ± SE. Differ-
ences between means were evaluated by one-way analysis of vari-
ance (ANOVA); *p < 0.05 versus control values.
Cell culture
HEK 293 cells, which stably express the human ghrelin receptor 1a 
(HEK-GHSR1a), were cultured as previously described (Lodeiro 
et al., 2009). 3T3-L1 preadipocyte cells were propagated and 
differentiated according to the protocol previously described 
(Gurriarán-Rodríguez et al., 2011). In brief, confluent 3T3-L1 cells 
were treated with 0.5 mM isobutylmethylxantine, 25 mM dexame-
thasone, and 861 nM (5 μg/ml) insulin for 3 d and maintained in 
DMEM containing 10% fetal bovine serum, 100 U/ml penicillin, and 
100 U/ml streptomycin, and supplemented with 172 nM (1 μg/ml) 
insulin for 10 d after the beginning of differentiation.
Animals
This study was carried out in strict accordance with the recommen-
dations in the “Guide for the Care and Use of Laboratory Animals” 
of the Faculty Animal Committee at the University of Santiago de 
Compostela, and the experiments were performed in agreement 
with the rules of laboratory animal care and international law on 
animal experimentation; all efforts were made to minimize suffer-
ing. Adult Swiss male mice (8 wk old) were housed in air-condi-
tioned rooms (22–24°C) under a 12:12 h light/dark cycle and fed 
with standard chow (SD) or HFD for 12 wk (D12451, 45 kcal% 
fat, Research Diets, New Brunswick, NJ). Food intake and body 
weight were measured weekly during the experimental phase. 
Animals were killed by decapitation between 10:00 and 12:00 h 
when they were 20 wk old. Excised WAT, omental and subcutane-
ous, was immediately transported to the laboratory in ice-cold 
Krebs-Ringer-HEPES buffer (HEPES, pH 7.4, 25 mM; NaCl, 
125 mM; KCl, 5 mM; MgSO4, 1.2 mM; CaCl2, 2 mM; KH2PO4, 
2 mM; glucose, 6 mM]. After blood vessels and conjunctive tissue 
were removed, adipose tissue was washed with sterile Krebs-
Ringer-HEPES buffer. Tissue fragments were placed in six-well 
dishes containing DMEM supplemented with penicillin (100 U/ml) 
and streptomycin sulfate (100 μg/ml). After a preincubation period 
of 1 h at 37°C under a humidified atmosphere of 95% air–5% CO2, 
the media were aspirated, and fresh medium, with or without ghre-
lin (100 nM, 10-min), was dispensed into each well. The media 
were then aspirated, and tissue samples were directly lysed in ice-
cold RIPA buffer (Tris-HCl, pH 7.2, 50 mM; NaCl, 150 mM; ethyl-
enediaminetetraacetic acid [EDTA], 1 mM; NP-40, 1% [vol/vol]; 
Na-deoxycholate, 0.25% [wt/vol]; protease inhibitor cocktail 
[Sigma-Aldrich; St. Louis, MO]; phosphatase inhibitor cocktail 
[Sigma]) for immunoblot analysis.
Plasmids and cell transient transfection
The catalytically inactive SHP-1/C453S (SHP-1dn; kind gift of 
T. Florio, University of Genova, Genova, Italy) mutant was used 
(Pagès et al., 1999). Cells (3 × 105) were transfected with 1 μg SHP-
1dn plasmid or vector control (pcDNA3) using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) as previously described (Theodoropoulou 
et al., 2006). Immunoblot analysis was used to confirm the SHP-1 
incorporation.
Immunoblot analysis
Serum-starved cells were stimulated with ghrelin for the indicated 
time period at 37°C. The medium was then aspirated and the cells 
were lysed in ice-cold RIPA buffer. Tissue samples were directly 
lysed in ice-cold RIPA buffer. The solubilized lysates were transferred 
into centrifuge tubes and left at 4°C for 15 min, then precleared by 
centrifuging at 13,000 × g for 15 min. Protein concentration was 
evaluated with the QuantiPro BCA assay kit (Sigma). Subsamples 
(same amount of protein) of each sample were separated on 
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